Cas:870997-82-3 2-methoxy-3-[(2-methylpropan-2-yl)oxycarbonylamino]pyridine-4-carboxylic acid manufacturer & supplier

We serve Chemical Name:2-methoxy-3-[(2-methylpropan-2-yl)oxycarbonylamino]pyridine-4-carboxylic acid CAS:870997-82-3 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

2-methoxy-3-[(2-methylpropan-2-yl)oxycarbonylamino]pyridine-4-carboxylic acid

Chemical Name:2-methoxy-3-[(2-methylpropan-2-yl)oxycarbonylamino]pyridine-4-carboxylic acid
CAS.NO:870997-82-3
Synonyms:3-[(t-butoxycarbonyl)amino]-2-methoxyisonicotinic acid;3-[(tert-butoxycarbonyl)amino]-2-methoxypyridine-4-carboxylic acid;3-(tert-butoxycarbonylamino)-2-methoxyisonicotinic acid
Molecular Formula:C12H16N2O5
Molecular Weight:268.26600
HS Code:2933399090

Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:97.75000
Exact Mass:268.10600
LogP:2.20840

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 3-[(t-butoxycarbonyl)amino]-2-methoxyisonicotinic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-(tert-butoxycarbonylamino)-2-methoxyisonicotinic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-(tert-butoxycarbonylamino)-2-methoxyisonicotinic acid Use and application,3-[(t-butoxycarbonyl)amino]-2-methoxyisonicotinic acid technical grade,usp/ep/jp grade.


Related News: UK-headquartered Verona announced at the beginning of the year that it had completed enrolment in a pilot study evaluating the efficacy of ensifentrine delivered via pressurised metered-dose inhaler (pMDI) formulation in patients hospitalised with COVID-19. Quinoline, 2-methoxy-6-(3-thienyl)- manufacturers AstraZeneca acquired global rights to anifrolumab through an exclusive license and collaboration agreement with Medarex, Inc. in 2004. Medarex was acquired by Bristol-Myers Squibb in 2009. 3-((2-((2-(2-(pyridin-4-yl)quinoline-8-carboxamido)ethyl)amino)ethyl)amino)benzo[e][1,2,4]triazine 1,4-dioxide suppliers But when it came to deciding on whether Americans with compromised immune systems should get an extra dose of any COVID-19 vaccine, the CDC said it would need to wait for the FDA to give its regulatory thumbs up first. That could come either through amending its emergency use nods or awarding full approvals. ethyl 4-(3-chloro-1,1,2,2,3,3-hexafluoropropyl)-1-methyl-1H-pyrazole-5-carboxylate vendor & factory.